Dynavax (DVAX) Gets a Buy Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (DVAXResearch Report), with a price target of $20.00. The company’s shares closed last Monday at $5.40.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.7% and a 50.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dynavax with a $16.50 average price target.

See today’s analyst top recommended stocks >>

Based on Dynavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $33.46 million. In comparison, last year the company had a GAAP net loss of $40.53 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.